2017 War on Skin Cancer Scientific Symposium

DATE: Sat., May 20, 2017
TIME: 8:30 a.m. – 3:15 p.m.
COST: Free. However, registration is still required.
LOCATION: Collaborative Life Sciences Building, Portland, Ore.
WHO: General practitioners, dermatologists, cancer care providers and researchers

Course objectives
This one-day course is designed for general practitioners, dermatologists, cancer care providers and researchers. OHSU Knight Cancer Institute physicians and expert guest speakers, including keynote speaker Dr. Jedd Wolchok from Memorial Sloan-Kettering Cancer Center in New York, will provide an overview of the latest advances in the prevention, risks, genetics and local and systemic treatment of melanoma. The course is free for all medical professionals.

At the conclusion of the course, participants will have learned how to:
1. Describe the immunologic basis of melanoma immunotherapy.
2. Describe common immune adverse events and how to treat them.
3. Discuss the role of molecular aberrations in melanoma and how they are used clinically.
4. Discuss the pros and cons of regional therapy options for melanoma.
5. Describe treatment options for uveal melanoma.
6. Describe the epidemiology of melanoma and how to best prevent melanoma.
7. Discuss hereditary melanoma and who should be referred for genetic testing.
8. Describe which patients are appropriate for Mohs surgery for melanoma.

Registration
Registration includes lunch on Saturday, May 20, and all course materials. Early registration is encouraged, as enrollment is limited.

Register online
www.ohsuknightcancer.com/melanomacme
# Agenda

**8:30 A.M.**
Registration and breakfast

**9 A.M.**
Introductory remarks
**SANCY LEACHMAN, M.D., PH.D.**
**KRISTEN MASSIMINO, M.D.**

**Session 1 – Systemic therapy for melanoma**

**9:10 A.M.**
Biologic basis of immunotherapy
**MATTHEW TAYLOR, M.D.**

**9:20 A.M.**
Checkpoint blockade
**MATTHEW TAYLOR, M.D.**

**9:30 A.M.**
Unwanted effects of immunotherapy
**BRENDAN CURTI, M.D.**

**9:40 A.M.**
Vaccines in the treatment of melanoma
**BRENDAN CURTI, M.D.**

**10:10 A.M.**
Gene expression profile tests
**SANCY LEACHMAN, M.D., PH.D.**

**10:30 A.M.**
Current approaches to uveal melanoma diagnosis and treatment
**ALISON SKELET, M.D., PH.D.**

**10:50 A.M.**
Tumor board, panel Q&A

**11:30 A.M.**
Lunch, panel discussion on hot topics for patients

**1 P.M.**
Gene expression profile tests
**SANCY LEACHMAN, M.D., PH.D.**

**1:10 P.M.**
Genetic testing for melanoma
**JONE SAMPSON, M.D.**

**1:20 P.M.**
Tumor board, panel Q&A

**1:30 P.M.**
Break

**Session 3 – Local therapy for melanoma**

**1:45 P.M.**
Current approaches to uveal melanoma diagnosis and treatment
**ALISON SKELET, M.D., PH.D.**

**2:05 P.M.**
Excise or refer?
**OLIVER WISCO, D.O.**

**2:15 P.M.**
Tumor microenvironment: the role of lymphatics
**AMANDA LUND, PH.D.**

**2:25 P.M.**
Evolution of lymph node management in melanoma
**JOHN VETTO, M.D.**

**2:35 P.M.**
Regional therapy for melanoma: resect, inject or infuse?
**KRISTEN MASSIMINO, M.D.**

**2:45 P.M.**
Central nervous system metastases
**JEREMY CIPOREN, M.D.**

**2:55 P.M.**
Tumor board, Q&A

**3:15 P.M.**
Adjourn